Gemtuzumab ozogamicin - Biologic Drug Details

Summary for gemtuzumab ozogamicin

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for gemtuzumab ozogamicin

Recent Clinical Trials for gemtuzumab ozogamicin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE2
M.D. Anderson Cancer Center	PHASE1
Kura Oncology, Inc.	PHASE1

See all gemtuzumab ozogamicin clinical trials

Pharmacology for gemtuzumab ozogamicin

Mechanism of Action	CD33-directed Antibody Interactions
Established Pharmacologic Class	CD33-directed Immunoconjugate

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for gemtuzumab ozogamicin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for gemtuzumab ozogamicin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	4,970,198	2007-11-13	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	5,079,233	2009-04-14	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	5,585,089	2015-06-07	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	5,606,040	2014-02-25	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	5,693,762	2015-06-07	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	5,739,116	2015-06-05	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	5,767,285	2015-06-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for gemtuzumab ozogamicin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	10,016,338	2036-12-20	Patent claims search
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	10,016,412	2036-12-09	Patent claims search
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	10,022,451	2035-05-11	Patent claims search
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	10,053,498	2035-11-20	Patent claims search
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	10,099,996	2033-09-12	Patent claims search
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	10,111,968	2036-08-10	Patent claims search
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	10,117,943	2033-05-03	Patent claims search

International Patents for gemtuzumab ozogamicin

Country	Patent Number	Estimated Expiration
South Africa	200503075
Cyprus	1116406
China	1795009
New Zealand	539395
Japan	2006505277
World Intellectual Property Organization (WIPO)	2011036183
Mexico	PA05004712

Gemtuzumab Ozogamicin: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is Gemtuzumab Ozogamicin and its Market Position?

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) targeting CD33. It is approved for the treatment of acute myeloid leukemia (AML). The drug's development and commercialization have been marked by a complex history of regulatory reviews and market re-entry. As an ADC, gemtuzumab ozogamicin combines a monoclonal antibody that targets CD33-expressing cancer cells with a potent cytotoxic agent, ozogamicin. This dual mechanism aims to deliver chemotherapy directly to leukemia cells, minimizing systemic toxicity.

The primary indication for gemtuzumab ozogamicin is for adult patients with newly diagnosed CD33-positive AML. It is also indicated for patients with relapsed or refractory CD33-positive AML. The market for AML therapeutics is characterized by a need for effective treatments, particularly for relapsed or refractory disease where options are limited and outcomes are poor. Gemtuzumab ozogamicin competes with other established chemotherapy regimens and newer targeted therapies entering the AML landscape.

The global AML market size was valued at approximately $2.5 billion in 2022 and is projected to reach $4.1 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.4% (Source: Global Market Insights). This growth is driven by an aging global population, increasing AML incidence, and advancements in treatment modalities, including targeted therapies and immunotherapies. Gemtuzumab ozogamicin's market share within this segment is influenced by its efficacy, safety profile, and reimbursement landscape, as well as the competitive pressures from other approved AML drugs.

What is the Regulatory and Patent Landscape for Gemtuzumab Ozogamicin?

Gemtuzumab ozogamicin has a significant regulatory history. It was initially approved by the U.S. Food and Drug Administration (FDA) in 2000 but was voluntarily withdrawn by its developer, Wyeth (now part of Pfizer), in 2010 due to safety concerns and lack of sufficient efficacy demonstrated in post-marketing studies. Following the development of revised clinical trial protocols and the demonstration of improved efficacy and safety in subsequent trials, the drug, under the brand name Mylotarg, received U.S. FDA approval for a second time in June 2017 for adult patients with relapsed or refractory CD33-positive AML. In September 2018, the FDA also approved Mylotarg for adult patients with newly diagnosed CD33-positive AML in remission after induction chemotherapy and as a single agent for those not eligible for intensive induction chemotherapy.

The patent landscape for gemtuzumab ozogamicin involves composition of matter patents, manufacturing process patents, and method of use patents. Key patents for the original development of gemtuzumab ozogamicin would have expired or are nearing expiration. However, new patents may cover specific formulations, manufacturing processes, or novel methods of use that extend market exclusivity. For instance, patents related to improved conjugation techniques, specific antibody modifications, or novel dosing regimens could provide additional layers of intellectual property protection.

The primary patent protection for the core composition of matter of gemtuzumab ozogamicin has expired. However, patent extensions and new patent filings related to manufacturing, formulations, and specific indications can extend effective market exclusivity. For example, patents covering the specific linker technology or the cytotoxic payload may provide ongoing protection. The expiration of key patents opens the door for generic or biosimilar competition, which could significantly impact pricing and market share.

What are the Financial Performance and Market Projections for Gemtuzumab Ozogamicin?

The financial performance of gemtuzumab ozogamicin is closely tied to its market re-entry and its positioning within the AML treatment paradigm. Following its re-approval, sales have shown a steady increase. For example, in 2022, net sales of Mylotarg globally were approximately $323 million (Source: Pfizer Investor Relations). This represents a significant recovery and growth trajectory compared to its initial market presence.

The market projections for gemtuzumab ozogamicin are influenced by several factors. The increasing incidence of AML, particularly in aging populations, provides a growing patient pool. Advancements in diagnostic tools that identify CD33 expression more accurately contribute to more precise patient selection. Furthermore, the drug’s demonstrated efficacy in both newly diagnosed and relapsed/refractory AML settings positions it as a valuable treatment option.

Key market drivers include:

• Increasing AML Incidence: Driven by aging demographics and improved diagnostics.
• Growing Demand for Targeted Therapies: Patients and physicians increasingly favor treatments with specific targets to improve efficacy and reduce side effects.
• Expansion into New Indications or Combinations: Potential for label expansions or inclusion in combination therapies could further boost sales.
• Emergence of Biosimilars: While current biosimilar activity is limited, it will eventually impact pricing and market dynamics.

Competitor products in the AML space include:

• Chemotherapy: Standard induction and consolidation regimens (e.g., cytarabine, daunorubicin).
• Targeted Therapies: FLT3 inhibitors (e.g., midostaurin, gilteritinib), IDH inhibitors (e.g., ivosidenib, enasidenib).
• Other ADCs: While not direct competitors in AML, other ADCs in oncology demonstrate the viability of this drug class.
• Hematopoietic Stem Cell Transplantation (HSCT): A curative option for eligible patients.

Market projections for gemtuzumab ozogamicin anticipate continued growth. Analysts forecast sales to reach approximately $500 million to $600 million by 2025, driven by wider adoption and potential label expansions. However, the exact trajectory will depend on the competitive landscape, pricing pressures from potential biosimilars, and the outcomes of ongoing clinical trials exploring its use in different AML patient subsets or in combination therapies.

What are the Key Challenges and Opportunities for Gemtuzumab Ozogamicin?

Challenges:

• Competitive Landscape: The AML market is increasingly crowded with novel agents, including other targeted therapies and immunotherapies. Established chemotherapy regimens remain a baseline treatment.
• Safety Profile and Monitoring: While improved, the drug carries risks of serious adverse events, including hepatotoxicity and myelosuppression, requiring careful patient monitoring.
• Reimbursement and Market Access: Navigating payer policies and securing favorable reimbursement is crucial, especially in the context of high-cost cancer therapies.
• Biosimilar Entry: As key patents expire, the threat of biosimilar competition looms, which could significantly erode market share and pricing power.
• Patient Selection Nuances: Ensuring accurate identification of CD33-positive AML is critical for optimal efficacy.

Opportunities:

• Expanding Label Indications: Further clinical trials could support approvals in broader AML patient populations or earlier lines of therapy.
• Combination Therapies: Investigating gemtuzumab ozogamicin in combination with other AML agents could enhance efficacy and address resistance mechanisms. This is a significant area of research for ADCs in oncology.
• Global Market Expansion: Pursuing regulatory approvals and market access in emerging markets could unlock new revenue streams.
• Advancements in ADC Technology: While not directly related to gemtuzumab ozogamicin's current formulation, ongoing innovation in ADC payloads, linkers, and antibody engineering could lead to next-generation conjugates with improved therapeutic windows.
• Real-World Evidence Generation: Continued collection and publication of real-world data can solidify the drug's value proposition and support its use by healthcare providers and payers.

The drug's continued success will depend on its ability to demonstrate sustained clinical benefit against evolving standards of care and manage the complexities of intellectual property and market competition.

Key Takeaways

• Gemtuzumab ozogamicin is an established ADC for adult CD33-positive AML, with a complex regulatory history and a successful re-introduction into the market.
• The drug generated approximately $323 million in global net sales in 2022, indicating a strong recovery and growth trajectory.
• While core composition of matter patents have expired, ongoing patent filings and extensions related to manufacturing, formulations, and specific uses may provide continued market exclusivity.
• The AML market is projected to grow, driven by increasing incidence and advancements in treatment, creating a favorable environment for effective therapies like gemtuzumab ozogamicin.
• Key challenges include a competitive market, potential for biosimilar entry, and the need for careful patient monitoring.
• Opportunities lie in expanding indications, exploring combination therapies, and global market expansion.

Frequently Asked Questions

1. What is the current patent protection status for gemtuzumab ozogamicin? Core composition of matter patents have expired. However, additional patents related to manufacturing processes, specific formulations, and novel methods of use may provide extended market exclusivity.

2. What are the main revenue drivers for gemtuzumab ozogamicin? Revenue drivers include its approved indications in newly diagnosed and relapsed/refractory CD33-positive AML, its demonstrated efficacy, and increasing adoption within the AML treatment landscape.

3. What is the anticipated impact of biosimilar competition on gemtuzumab ozogamicin? Biosimilar competition, once it enters the market, is expected to lead to significant price reductions and a potential decrease in market share for the originator product.

4. How does gemtuzumab ozogamicin compare to other AML treatments in terms of efficacy and safety? Gemtuzumab ozogamicin offers a targeted approach with demonstrated efficacy in specific AML subsets. Its safety profile, while manageable with monitoring, includes risks of hepatotoxicity and myelosuppression, necessitating careful patient selection and management.

5. What future developments are most likely to impact the market trajectory of gemtuzumab ozogamicin? Future impacts will likely stem from the development and approval of combination therapies, potential label expansions into earlier lines of treatment or broader patient populations, and the eventual emergence of biosimilars.

---

Sources

[1] Global Market Insights. (2023). Acute Myeloid Leukemia (AML) Market Size, Share & Trends Analysis Report. [2] Pfizer Inc. (2023). Pfizer 2022 Annual Report. [3] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages: Mylotarg. Retrieved from [FDA website] (Note: Specific URL depends on the FDA's current website structure and may require searching for the drug name).